Umary Acido Hialuronico, Suplemento Alimenticio, 850 mg caplets, packaged in 30-count bottles.
Published August 7, 2024 · Recall initiated: July 12, 2024
Summary
FDA records drug Class I recall D-0620-2024, published August 7, 2024 and initiated July 12, 2024. Recalling firm: SoloVital; Status: Ongoing; Reported quantity: 1,331 bottles; Lot: All lots within Expiry. Class I means a reasonable probability of serious adverse health consequences or death.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Marketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared Diclofenac and Omeprazole.
What to do
Voluntary: Firm initiated · E-Mail
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- SoloVital
- Distributor
- Nationwide within the United States
- Lot
- All lots within Expiry
- Risk classification
- Class I
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAPotassium Chloride Extended-Release Capsules, USP, (750 mg) 10 mEq K, a).100-count bottle ( NDC 68001-396-00),August 7, 2024
- FDAGlenmark, Azelaic Acid Gel, 15 %, 50 grams, Rx only, Manufactured by: Glenmark Pharmaceuticals Limited,August 7, 2024
- FDAClonazepam Orally Disintegrating Tablets, USP (C-IV) 0.125mg, 60 tablets per carton (10 blister cardsAugust 7, 2024
- FDACiprofloxacin ophthalmic solution USP, 0.3% as base, package in bottles: a) 10 mL (NDC 69315-308-10), b) 2.5August 7, 2024
- FDALINK SymphoKnee Patella Sizing Template, Item Number 881-509/00July 31, 2024
- FDASensis Vibe systems with software version VD15B-Intended to be used as a diagnostic and administrative toolJuly 31, 2024
Questions about this recall
Was Umary Acido Hialuronico, Suplemento Alimenticio, 850 mg caplets, packaged in 30-count bottles. recalled?
Yes. FDA published recall D-0620-2024 on August 7, 2024. Reported hazard: Marketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared Diclofenac and Omeprazole.
What should I do if I have this product?
Voluntary: Firm initiated · E-Mail